Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands
Open accessThe DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Abstract
Hormone-dependent cancers, such as certain types of breast cancer are characterized by over-expression of estrogen receptors (ERs). Anticancer drug conjugates combining ER ligands with other classes of anticancer agents may not only benefit from dual action at both anti-cancer targets but also from selective delivery of cytotoxic agents to ER-positive tumor cells resulting in less toxicity and adverse effects. Moreover, they could also take advantage of overcoming resistance typical for anti-hormonal monotherapy such as tamoxifen. In this review, we discuss the design, structures and pharmacological effects of numerous series of drug conjugates containing ER ligands such as selective ER modulators (tamoxifen, 4-hydroxytamoxifen, endoxifen), selective ER degraders (ICI-164384) and ER agonists (estradiol) linked to diverse anti-cancer agents including histone-deacetylase inhibitors, DNA-alkylating agents, antimitotic agents and epidermal growth factor receptor inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The released 4-OH-TAM exerts a direct anti-estrogenic effect, thereby mitigating the unsatisfactory therapeutic outcomes associated with the differences in TAM metabolism.”
From Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer.”
From Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444 · cited 1×
“Breast cancer is the most common type of neoplasia among women [11].”
BackgroundLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Especially the hybrid ligands with the pharmacophores connected by longer spacers are large chemical entities with molecular mass exceeding 500 Da and often high lipophilicity and violate Lipinski’s [47] and Veber’s [48] rules that assess molecular properties influencing oral bioavailability.”
BackgroundDesigned Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209 · cited 1×
“A challenge for the design and development of drug conjugates as anticancer therapeutics is the optimization of their physicochemical properties towards a favorable pharmacokinetic profile [46].”
BackgroundJin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951 · cited 2×
“Structures of major metabolites of tamoxifen, their plasma concentrations in women taking tamoxifen [36], their antagonist activities at ERα [29] and binding affinities to rat uterine ERs [37].”
BackgroundAntibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786 · cited 1×
“While ADCs have been successfully introduced as cancer therapeutics [5], hybrid anticancer agents have mostly been reported in preclinical studies [4].”
BackgroundMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651 · cited 1×
“However, its chronic use can increase the risk of uterine cancer [20] and induce tamoxifen resistance [21].”
BackgroundWijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427 · cited 1×
“Moreover, SERDs are known to induce ubiquitination and degradation of ERα through the proteasome pathway [16].”
BackgroundUpdate on melatonin receptors: IUPHAR Review 20
Jockers, R., Delagrange, P., Dubocovich, M. L., Markus, R. P., Renault, N., Tosini, G., Cecon, E., & Zlotos, D. P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13536 · Cited by 422 · cited 1×
“The higher MT1-affinity of compound 3 compared to the parent drug is rather surprising taking into account that according to the well-established SARs, alkyl substituents larger than propyl attached to the amide carbonyl group of melatonin reduce binding affinity to melatonin receptors [33,34].”
BackgroundSelf-citationCoezy, E. D., Borgna, J., & Rochefort, H. (1982) · PubMed · Cited by 394
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 375 · cited 1×
“Anticancer drug conjugates incorporate two drugs (pharmacophores) in one molecule exerting synergistic action at two different cancer targets [3].”
BackgroundRecent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295 · cited 1×
“Anticancer drug conjugates (hybrid anticancer agents) are an emerging approach to overcome drawbacks of current anticancer treatment, such as insufficient potency and efficacy, high toxicity, and development of resistance [1,2].”
BackgroundKatzenellenbogen, B. S., Norman, M. J., Eckert, R. L., Peltz, S. W., & Mangel, W. F. (1984) · PubMed · Cited by 276
Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., & Qian, C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901453q · Cited by 264 · cited 2×
“Recent examples are CUDC-101 (MW 434), a dually acting chimeric EGFR/HDAC inhibitor [7,8]; fimepinostat (CUDC-907, MW 509), a dual HDAC-PI3K inhibitor [9]; tinostamustine (MW 415), a fusion molecule composed of an alkylating agent bendamustine and HDAC inhibitor vorinostat [49].”
BackgroundEstrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E., Ariazi, J., Cordera, F., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776173483 · Cited by 255
Biological Role of Estrogen and Estrogen Receptors
Nilsson, S., & Gustafsson, J.-Å. (2002) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230290771438 · Cited by 244 · cited 2×
“Estrogens, such as 17βestradiol (Figure 1) are essential for the development of female sexual features including breast growth [12].”
BackgroundEstrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E. A., & Jordan, V. C. (2008) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527623297.ch5 · Cited by 230 · cited 1×
“Inhibition of estrogenic stimulation of ERα is therefore a widely used strategy in the pharmacotherapy of breast cancer [15].”
MethodAdvances in the development of hybrid anticancer drugs
Fortin, S., & Bérubé, G. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.798296 · Cited by 223 · cited 1×
“Anticancer drug conjugates (hybrid anticancer agents) are an emerging approach to overcome drawbacks of current anticancer treatment, such as insufficient potency and efficacy, high toxicity, and development of resistance [1,2].”
BackgroundDiversity in the mechanisms of gene regulation by estrogen receptors
Sanchez, R., Nguyen, D., Rocha, W., White, J. H., & Mader, S. (2002) · BioEssays · doi:10.1002/bies.10066 · Cited by 199 · cited 2×
“They regulate gene expression by binding to DNA response elements associated with target genes [13].”
BackgroundEstrogen and progesterone receptors in the normal female breast.
Ricketts, D., Turnbull, L. A., Ryall, G., bakhshi, R. K., Rawson, N. S. B., Gazet, J.-C., Nolan, C., & Coombes, R. C. (1991) · PubMed · Cited by 197
Younes, A., Berdeja, J. G., Patel, M. R., Flinn, I., Gerecitano, J. F., Neelapu, S. S., Kelly, K. R., Copeland, A. R., Akins, A., Clancy, M. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00584-7 · Cited by 186 · cited 2×
“Recent examples are CUDC-101 (MW 434), a dually acting chimeric EGFR/HDAC inhibitor [7,8]; fimepinostat (CUDC-907, MW 509), a dual HDAC-PI3K inhibitor [9]; tinostamustine (MW 415), a fusion molecule composed of an alkylating agent bendamustine and HDAC inhibitor vorinostat [49].”
BackgroundMT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential
Zlotos, D. P., Jockers, R., Cecon, E., Rivara, S., & Witt-Enderby, P. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401343c · Cited by 175 · cited 1×
“The higher MT1-affinity of compound 3 compared to the parent drug is rather surprising taking into account that according to the well-established SARs, alkyl substituents larger than propyl attached to the amide carbonyl group of melatonin reduce binding affinity to melatonin receptors [33,34].”
BackgroundSelf-citationLissoni, P., Barni, S., Meregalli, S., Fossati, V, Cazzaniga, M., Esposti, D., & Tancini, G. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.164 · Cited by 150
Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance
Jordan, V. C., & Chem, C. (1982) · Breast Cancer Research and Treatment · doi:10.1007/bf01806449 · Cited by 149 · cited 7×
“Interestingly, the more pronounced antiestrogen activity of 4-OH-tamoxifen correlates with its higher growth inhibition of ER-positive MCF-7 plasma concentration 363 nM 655 nM 9 nM 63 nM ERα antagonist action from luciferase reporter as ay IC50 49 nM - 0.21 nM 0.14 nM Inhibition of [3 ]- str i l binding to rat uterine…”
BackgroundInfluentialHill, S. M., Spriggs, L. L., Simon, M. A., Muraoka, H., & Blask, D. E. (1992) · Cancer Letters · doi:10.1016/0304-3835(92)90050-6 · Cited by 138
Melatonin blocks the activation of estrogen receptor for DNA binding
Rato, A. G., Pedrero, J. G., Martínez, M. A., Del Rio, B., Lazo, P. S., & Ramos, S. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.857 · Cited by 126
Hybrid Compounds as Multitarget Directed Anticancer Agents
Küçüksayan, E., & Özben, T. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160927155515 · Cited by 108 · cited 2×
“While ADCs have been successfully introduced as cancer therapeutics [5], hybrid anticancer agents have mostly been reported in preclinical studies [4].”
BackgroundWall, M. E., Abernethy, G. S., Carroll, F. I., & Taylor, D. J. (1969) · Journal of Medicinal Chemistry · doi:10.1021/jm00305a021 · Cited by 105 · cited 1×
“Research on hybrid ligands coupling alkylating agents to steroids in the late 1960s led to discovery of estramustine phosphate, an approved anti-prostate cancer drug [17].”
BackgroundJones, M. E., van Leeuwen, F. E., Hoogendoorn, W. E., Mourits, M. J. E., Hollema, H., van Boven, H., Press, M. F., Bernstein, L., & Swerdlow, A. J. (2012) · Breast Cancer Research · doi:10.1186/bcr3206 · Cited by 98 · cited 1×
“However, its chronic use can increase the risk of uterine cancer [20] and induce tamoxifen resistance [21].”
BackgroundHistone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
Gryder, B. E., Rood, M. K., Johnson, K. A., Patil, V., Raftery, E. D., Yao, L.-P. D., Rice, M., Azizi, B., Doyle, D. F., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400467w · Cited by 93 · cited 4×
“55 μM Z-4-OH-tamoxifen 10 nM 150 nM ICI-164384 50 nM 930 nM vorinostat 320 nM 350 nM 170 nM entinostat 350 nM 310 nM 19 22 μM 22 μM 8 nM [28] estradiol vorinostat 4.”
BackgroundInfluentialKatzenellenbogen, B. S., Carlson, K. E., & Katzenellenbogen, B. S. (1985) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(85)90210-9 · Cited by 91 · cited 2×
“For example, 20% of (Z)-4-OH-tamoxifen was reported to have isomerized to the corresponding (E)-isomer after 2 days at 37 °C in tissue culture medium including estrogen receptor-positive MCF-7 human breast cancer cells [41].”
BackgroundMelatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro
Wilson, S. T., Blask, D. E., & Lemus-Wilson, A. M. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.2.1639964 · Cited by 74
Targeting the Estrogen Receptor using Steroid–Therapeutic Drug Conjugates (Hybrids)
Dao, K.-L., & Hanson, R. N. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300378e · Cited by 73 · cited 2×
“by Dao and Hanson critically summarized advances in the field of targeting the estrogen receptor by anticancer steroid–drug conjugates till 2012 [18].”
BackgroundMalet, C., Gompel, A., Spritzer, P. M., Bricout, N., Yaneva, H., Mowszowicz, I., Kuttenn, F., & MAUVAIS-JARVIS, P. (1988) · PubMed · Cited by 59
Shalini, S., & Kumar, V. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1850686 · Cited by 57
Drug conjugates—an emerging approach to treat breast cancer
Hasan, M., Leak, R. K., Stratford, R. E., Zlotos, D. P., & Witt‐Enderby, P. A. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.417 · Cited by 50 · cited 1×
“Most anticancer drug conjugates target breast cancer, as recently reviewed [10].”
BackgroundSelf-citationHasan, M., Marzouk, M. A., Adhikari, S., Wright, T. D., Miller, B. P., Matossian, M. D., Elliott, S. G., Wright, M. K., Alzoubi, M. S., Collins‐Burow, B. M., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.116202 · Cited by 44
Self-citationDesign, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids
Mendoza‐Sanchez, R., Cotnoir‐White, D., Kulpa, J., Jutras, I., Pottel, J., Moitessier, N., Mader, S., & Gleason, J. L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.005 · Cited by 38 · cited 2×
“Hybrid ligands combining the pure antiestrogen and SERD ICI-164384 (Figure 1) with the HDAC inhibitors structurally related to vorinostat (16a and 16b) and entinostat (17) nd a benzhydroxamic acid analog 18 rted [45].”
MethodKelly, P. M., Keely, N. O., Bright, S. A., Yassin, B., Ana, G., Fayne, D., Zisterer, D. M., & Meegan, M. J. (2017) · Molecules · doi:10.3390/molecules22091440 · Cited by 35 · cited 2×
“A conjugate molecule 4 incorporating tamoxifen connected to an antimitotic and tubulin targeting agent combretastatin A-4 through a succinic acid ester linkage was reported to display comparable binding affinity to ERα to that of endoxifen, the active metabolite of tamoxifen (IC50 = 80 nM and 47 nM, respectively) [31].”
BackgroundFröhlich, T., Mai, C., Bogautdinov, R. P., Morozkina, S. N., Shavva, A. G., Friedrich, O., Gilbert, D. F., & Tsogoeva, S. B. (2020) · ChemMedChem · doi:10.1002/cmdc.202000174 · Cited by 34 · cited 2×
“Other pharmacological data were not reported [32].”
MethodMehrling, T., & Chen, Y. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150518092027 · Cited by 33 · cited 1×
“Recent examples are CUDC-101 (MW 434), a dually acting chimeric EGFR/HDAC inhibitor [7,8]; fimepinostat (CUDC-907, MW 509), a dual HDAC-PI3K inhibitor [9]; tinostamustine (MW 415), a fusion molecule composed of an alkylating agent bendamustine and HDAC inhibitor vorinostat [49].”
BackgroundGefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer
Abdelmalek, C. M., Hu, Z., Kronenberger, T., Küblbeck, J., Kinnen, F., Hesse, S. S., Malik, A., Kudolo, M., Nieß, R., Gehringer, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01646 · Cited by 31 · cited 4×
“The hybrid ligand 6b is a direct analog of the tamoxifen-gefitinib drug conjugate 2b (Table 1) with the tamoxifen part replaced by (Z)-4-OH-tamoxifen [29].”
BackgroundInfluentialSelf-citationZhang, X., Zhang, B., Liu, J., Liu, J., Li, C., Dong, W., Fang, S., Li, M., Song, B., Tang, B., et al. (2015) · Scientific Reports · doi:10.1038/srep07835 · Cited by 29 · cited 2×
“Several studies indicated that particular anticancer agents including the EGFR inhibitor gefitinib [22], the HDAC inhibitor vorinostat [23], and the neurohormone melatonin [24–27], may reverse acquired resistance to tamoxifen making a possible combination therapy more effective compared to single treatment with tamoxi…”
BackgroundPalermo, A. F., Diennet, M., Ezzy, M. E., Williams, B. M., Cotnoir‐White, D., Mader, S., & Gleason, J. L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.026 · Cited by 19 · cited 1×
“Hybrid ligands 15a and 15b are (Z/E)-4-OH-tamoxifen analogs with the phenyl group substituted in the para position with the Zn-chelating hydroxamic acids -(CH2)4CONHOH and -O(CH2)4CONHOH, respectively, that are structurally related to the HDAC inhibitor vorinostat [44].”
BackgroundTargeting Tumors Using Estrogen Receptor Ligand Conjugates
Keely, N. O., & Meegan, M. J. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166628 · Cited by 17 · cited 1×
“For drug conjugates incorporating more structurally diverse estrogen receptor ligands reported before 2009, the reader is referred to an excellent review “Targeting Tumors Using Estrogen Receptor Ligand Conjugates” by Keely and Meegan [19].”
BackgroundKeely, N. O., Carr, M. J., Yassin, B., Ana, G., Lloyd, D. G., Zisterer, D. M., & Meegan, M. J. (2016) · Biomedicines · doi:10.3390/biomedicines4030015 · Cited by 17
Münster, P. N., Lacevic, M., Thomas, S., Ismail-Khan, R. R., Rugo, H. S., Melisko, M. E., & Minton, S. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-6100 · Cited by 8 · cited 2×
“Several studies indicated that particular anticancer agents including the EGFR inhibitor gefitinib [22], the HDAC inhibitor vorinostat [23], and the neurohormone melatonin [24–27], may reverse acquired resistance to tamoxifen making a possible combination therapy more effective compared to single treatment with tamoxi…”
BackgroundKeely, N. O., Zisterer, D. M., & Meegan, M. J. (2012) · Letters in Drug Design & Discovery · doi:10.2174/157018012799129864 · Cited by 4
Research works printed but not linked: 2
- (2022, December 22). Available online: https://pubmed.ncbi.nlm.nih.gov/?term=anticancer+hybrids.
- (2022, December 22). Available online: https://adisinsight.springer.com/drugs/800028795.
Cited by
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 77
Martino, S. D., & Rosa, M. D. (2024) · Topics in Current Chemistry · doi:10.1007/s41061-024-00477-6 · Cited by 39
Galvani, F., Cammarota, M., Vacondio, F., Rivara, S., & Boscia, F. (2024) · Journal of Pineal Research · doi:10.1111/jpi.70008 · Cited by 25
Wang, L., Guo, X., Qin, J., Jin, Z., Liu, Q., Sun, C., Sun, K., Li, L., Wei, X., & Zhang, Y. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07225-y · Cited by 8
Ryzhikova, O. V., Churkina, A. S., Sedenkova, K. N., Savchenkova, D. V., Shakhov, A. S., Lavrushkina, S. V., Grishin, Y. K., Зефиров, Н. А., Zefirova, O. N., Gracheva, Y. A., et al. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400483 · Cited by 3
Metadata
- Authors
- Zlotos, D. P., Kronenberger, T., & Laufer, S. A.
- Affiliations
- German University in Cairo (EG)
- Universitätsklinikum Tübingen (DE)
- University of Tübingen (DE)
- Corresponding author
- Zlotos, Darius P.
- Laufer, Stefan A.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-12-26
- Volume
- 15
- Issue
- 1
- Pages
- 67
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9866829
- OpenAlex
- W4313245134
- Cited by
- 9
- References
- 52
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- German Academic Exchange Service (Sustainable Research Cooperation between GUC and Tuebingen University)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- estrogen receptor ligands, hormone-dependent breast cancer, tamoxifen, endoxifen, 4-hydroxytamoxifen, selective estrogen receptor modulators, selective estrogen receptor degrader, estradiol, histone deacetylase inhibitors, DNA alkylating agents, antimitotic agents, EGFR inhibitors, targeted drug delivery, tamoxifen resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.